<DOC>
	<DOCNO>NCT01236443</DOCNO>
	<brief_summary>A Study identify toxicity optimal photodynamic treatment parameter use photosensitizer 2- [ 1-hydroxyethyl ] -2-devinylpyropheophorbide-a ( HPPH ) high grade dysplasia , carcinoma-in-situ , early adenocarcinoma Barrett 's esophagus .</brief_summary>
	<brief_title>Study Photodynamic Therapy ( PDT ) Using HPPH Barrett 's Esophagus</brief_title>
	<detailed_description />
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>Patient must biopsy proven highgrade ( severe ) dysplasia , carcinomainsitu early stage adenocarcinoma ; Patient may receive prior therapy ; e.g . NdYAG laser , radiation therapy chemotherapy . At least one month must elapse prior treatment PDT . Tumors primary recurrent , Stage 0 I , N0M ( ) . Patients must contraindications endoscopy . Male female patient must 18 year old old . Female patient must pregnant must practice medically acceptable form birth control sterile postmenopausal . A pregnancy test require must negative . Patients must sign Informed Consent accord FDA guideline acceptable RPCI IRB . Patients must Karnofsky status 50 . Operable patient exclude . Patients tumor grade great T1 . Porphyria hypersensitivity porphyrin porphyrinlike compound . WBC &lt; 2,000 ; platelet count &lt; 50,000 , prothrombin time 1.5 time upper normal limit . Patients impaired renal and/or hepatic function ( total serum bilirubin &gt; 3.0 mg/d , serum creatinine &gt; 3 mg % , alkaline phosphatase ( hepatic ) SGOT &gt; 3 time upper normal limit . Patients concurrent chemotherapy radiation therapy exclude well receive prior treatment esophageal cancer within 4 week enrollment . If patient cancer nonmelanoma skin cancer must deem disease free treat physician .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>